{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:08:49Z","timestamp":1789398529382,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Children with risk conditions are vulnerable to invasive pneumococcal disease (IPD) and are targeted for routine and supplemental pneumococcal vaccination. This study aimed to quantify the incidence of IPD in US children by risk group since pneumococcal conjugate vaccine introduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Invasive pneumococcal disease episodes were identified in the Merative\u2122 MarketScan\u00ae Commercial Database (1998-2023) and Multi-State Medicaid Database (2001-2023) using inpatient and outpatient claims. Annual IPD incidence rates (IRs) were calculated as episodes per 100\u2009000 person-years (PY) for children &amp;lt;18\u00a0years of age, overall and by insurance type, age, and risk group. Incidence rate ratios (IRRs) were calculated to compare IR for children with chronic medical conditions (CMC) and immunocompromising conditions (IC) with those with no CMC\/IC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3538 commercially-insured and 3268 Medicaid-insured children with \u22651 IPD episode were identified among 128.9 million (121.9 million PYs) and 71.2 million eligible children (65.4 million PYs), respectively. Across age and risk groups, IPD IRs decreased over time, regardless of insurance type. Commercially-insured children with CMC and IC had 3.1-8.6 and 19.1-74.5 times higher IPD IRs, respectively, than those without CMC\/IC, with similar patterns in the Medicaid database. Invasive pneumococcal disease IRs were the highest among children &amp;lt;2\u00a0years, while risk-group disparities were greater among older children. Incidence rate ratios comparing CMC and IC vs. no CMC\/IC increased over time, indicating widening disparities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Invasive pneumococcal disease IRs among children with CMC\/IC remain substantially higher than those without CMC\/IC, and IRRs for children with risk conditions have increased over time. The risk-group disparities were more pronounced in older children. Better prevention strategies are needed to prevent IPD in children with risk conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpids\/piag084","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:40:20Z","timestamp":1788025220000},"source":"Crossref","is-referenced-by-count":0,"title":["Incidence of Invasive Pneumococcal Disease in US Children by Risk Group, 1998-2023"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-6467","authenticated-orcid":false,"given":"Salini","family":"Mohanty","sequence":"first","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolae","family":"Done","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Wang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Zion","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Reichert","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayler","family":"Li","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"White","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsie","family":"Cassell","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ling","family":"Huang","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica P","family":"Weaver","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly D","family":"Johnson","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Banniettis","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A","family":"Feemster","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"2026091410315361100_ref1","article-title":"Active bacterial core surveillance report, emerging infections program network, Streptococcus pneumoniae","author":"Centers for Disease Control and Prevention","year":"2022"},{"key":"2026091410315361100_ref2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-063039","article-title":"Invasive pneumococcal disease after 2 decades of pneumococcal conjugate vaccine use","volume":"153","author":"Yildirim","year":"2024","journal-title":"Pediatrics."},{"key":"2026091410315361100_ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-14051-6","article-title":"Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018","volume":"22","author":"Hu","year":"2022","journal-title":"BMC Public Health"},{"key":"2026091410315361100_ref4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(14)70032-3","article-title":"Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis","volume":"2","author":"Simonsen","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026091410315361100_ref5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/cid\/ciu348","article-title":"Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine","volume":"59","author":"Pelton","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026091410315361100_ref6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/ijcp.12234","article-title":"The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe","volume":"68","author":"Rose","year":"2014","journal-title":"Int J Clin Pract"},{"key":"2026091410315361100_ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75691-5","article-title":"Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency","volume":"10","author":"Lochen","year":"2020","journal-title":"Sci Rep"},{"key":"2026091410315361100_ref8","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","article-title":"Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease","volume":"70","author":"Torres","year":"2015","journal-title":"Thorax."},{"key":"2026091410315361100_ref9","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1016\/j.vaccine.2018.07.039","article-title":"The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis","volume":"36","author":"van Aalst","year":"2018","journal-title":"Vaccine."},{"key":"2026091410315361100_ref10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ejim.2013.02.013","article-title":"Chronic heart failure and risk of hospitalization with pneumonia: a population-based study","volume":"24","author":"Mor","year":"2013","journal-title":"Eur J Intern Med"},{"key":"2026091410315361100_ref11","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1200","article-title":"Asthma and the risk of invasive pneumococcal disease: a meta-analysis","volume":"145","author":"Castro-Rodriguez","year":"2020","journal-title":"Pediatrics."},{"key":"2026091410315361100_ref12","doi-asserted-by":"publisher","first-page":"e31467","DOI":"10.1002\/pbc.31467","article-title":"Prevention of invasive pneumococcal disease among black or African American children with and without sickle cell disease in the United States after introduction of 13-valent pneumococcal conjugate vaccine, 2005 through 2019","volume":"72","author":"Payne","year":"2025","journal-title":"Pediatr Blood Cancer"},{"key":"2026091410315361100_ref13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/INF.0000000000004730","article-title":"Characteristics of invasive pneumococcal diseases cases among US children with hematologic malignancies before and after introduction of thirteen-valent pneumococcal conjugate vaccine, 2005\u20132019","volume":"44","author":"Hamilton","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"2026091410315361100_ref14","first-page":"258","article-title":"Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - advisory committee on immunization practices (ACIP), 2010","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026091410315361100_ref15","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP)","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026091410315361100_ref16","first-page":"521","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP)","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026091410315361100_ref17","doi-asserted-by":"publisher","first-page":"944","DOI":"10.15585\/mmwr.mm6434a4","article-title":"Intervals between PCV13 and PPSV23 vaccines: recommendations of the advisory committee on immunization practices (ACIP)","volume":"64","author":"Kobayashi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026091410315361100_ref18","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.15585\/mmwr.mm7137a3","article-title":"Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the advisory committee on immunization practices\u2014United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly rep"},{"key":"2026091410315361100_ref19","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7239a5","article-title":"ACIP updates: recommendations for use of 20-valent pneumococcal conjugate vaccine in children\u2014United States, 2023","volume":"72","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026091410315361100_ref20","author":"Centers for Disease Control and Prevention"},{"key":"2026091410315361100_ref21","doi-asserted-by":"publisher","first-page":"6751","DOI":"10.1182\/bloodadvances.2022009643","article-title":"Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines","volume":"7","author":"Adamkiewicz","year":"2023","journal-title":"Blood Adv"},{"key":"2026091410315361100_ref22","doi-asserted-by":"publisher","first-page":"127193","DOI":"10.1016\/j.vaccine.2025.127193","article-title":"Serotype specific pneumococcal vaccine effectiveness in children with sickle cell disease: a two-decade analysis","volume":"56","author":"Zhang","year":"2025","journal-title":"Vaccine."},{"key":"2026091410315361100_ref23","volume-title":"Merative MarketScan Research Databases: Commercial Database & Medicare Database User Guide\u2014Data Year 2023","year":"2023"},{"key":"2026091410315361100_ref24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/jama.2010.104","article-title":"Dynamics of obesity and chronic health conditions among children and youth","volume":"303","author":"Van Cleave","year":"2010","journal-title":"JAMA."},{"key":"2026091410315361100_ref25","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.5888\/pcd12.140397","article-title":"Multiple chronic conditions among outpatient pediatric patients, southeastern Michigan, 2008\u20132013","volume":"12","author":"Rezaee","year":"2015","journal-title":"Prev Chronic Dis"},{"key":"2026091410315361100_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.acap.2025.102810","article-title":"Prevalence and trends in pediatric-onset chronic conditions in the United States, 1999\u20132018","volume":"25","author":"Wisk","year":"2025","journal-title":"Acad Pediatr"},{"key":"2026091410315361100_ref27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/1059840516641190","article-title":"Prevalence and costs of five chronic conditions in children","volume":"32","author":"Miller","year":"2016","journal-title":"J Sch Nurs"},{"key":"2026091410315361100_ref28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1542\/peds.2014-2426","article-title":"Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease","volume":"135","author":"Yildirim","year":"2015","journal-title":"Pediatrics."},{"key":"2026091410315361100_ref29","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1016\/j.vaccine.2016.10.050","article-title":"Pneumococcal conjugate vaccine failure in children: a systematic review of the literature","volume":"34","author":"Oligbu","year":"2016","journal-title":"Vaccine."},{"key":"2026091410315361100_ref30","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-031724","article-title":"Improving pneumococcal vaccination rates in high-risk children in specialty clinics","volume":"149","author":"Harris","year":"2022","journal-title":"Pediatrics"},{"key":"2026091410315361100_ref31","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1093\/infdis\/jiaf376","article-title":"Pneumococcal serotype distribution and coverage of existing and pipeline pneumococcal vaccines","volume":"232","author":"King","year":"2025","journal-title":"J Infect Dis"},{"key":"2026091410315361100_ref32","doi-asserted-by":"publisher","volume-title":"Hum Vaccin Immunother","author":"Jagannath","DOI":"10.1080\/21645515.2026.2684089"},{"key":"2026091410315361100_ref33","author":"U.S. Food and Drug Administration"},{"key":"2026091410315361100_ref34","author":"Mykyta"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piag084\/70868030\/piag084.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/15\/9\/piag084\/70868030\/piag084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/15\/9\/piag084\/70868030\/piag084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:32:01Z","timestamp":1789396321000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/doi\/10.1093\/jpids\/piag084\/8775950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,14]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piag084","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,29]]},"article-number":"piag084"}}